% | $
Quotes you view appear here for quick access.

Zogenix, Inc. Message Board

  • ridikulusrumors ridikulusrumors Jan 10, 2014 10:16 PM Flag

    It's down to MNK and ENDP!

    I'm hearing $13.50

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ENDP's buy range for small cap companies is $1m-$500m. Nasdaq lists ZGNX's market cap at $596.75m which puts it out of ENDP's price range. ENDP is overleveraged with all their recent acquisitions while MNK has lots of cash on hand. A $1billion valuation of ZGNX(assuming Zohydro will be a blockbuster) is worth about $7 per share; add Sumavel Dosepro revenues and your looking at close to $9. A multi-billion dollar valuation puts it sky high. I think MNK can afford that.

      If ENDP was to make another acquisition it would probably be BDSI since they currently have a world-wide licensing agreement for BEMA Buprenorphine for pain. BDSI's current market cap is about $236.63m which is in ENDP's price range. A $500m valuation of BDSI (ENDP's high range for small caps) is worth about $13 per share. BDSI has a PDUFA scheduled in June'14 for Bunavail, and phase 3 results for BEMA Buprenorphine due 1Q and 2Q 2014.

      Sentiment: Strong Buy

19.76+0.13(+0.66%)Sep 4 3:59 PMEDT